Nasdaq:AVCO

RNA-Based Chimeric Antigen Receptor (CAR) Design Compatible with Broad Range of Immune Effector Cells, Including T (CAR-T) and Natural Killer Cells (CAR-NK) Without the Use of Viral Vectors Capable of Targeting Multiple Tumor Antigens for Potentially Superior Therapeutic Effects Rapid 1-2 Day Bio-manufacturing Time to Quickly Meet Treatment Needs in Patients with Relapsed/Refractory Leukemia, Lymphoma …